Medical experts across Europe are calling for urgent upgrades to life-saving anaphylaxis treatment devices. A new survey reveals significant limitations in current adrenaline auto-injector technology despite their status as first-line treatments.
Researchers from the European Anaphylaxis Registry gathered data from 175 doctors between March and April 2025. Results indicate that extended shelf life and optimized storage conditions top the priority list for future design. Doctors also emphasized the need for needle-free options and better dose precision.
Yet, widespread adoption faces hurdles; roughly 75% of clinicians insist on formal society endorsements and deeper clinical evidence before transitioning to new systems. While primarily opinion-based, this data underscores the necessity for innovation in emergency allergy care infrastructure to ensure broader patient accessibility.